$ATEC Lake Street assumed coverage of Alphatec with a Buy rating and $18 price target. Alphatec represents "the only scaled spine player totally focused on improving spine outcomes," while much of the industry "borders on totally confused," argues the analyst, who expects the company's "outsized" growth to continue.